Table 1.
Systemic characteristics at endpoint
| Systemic characteristics | Non-diabetic | Diabetic | ||
|---|---|---|---|---|
| Vehicle | Lipoxin A4 | Vehicle | Lipoxin A4 | |
| Heart (mg) | 163.0 ± 5.8 (n = 28) | 159.5 ± 3.2 (n = 31) | 116.5 ± 2.5## (n = 18) | 105.9 ± 2.7$ (n = 16) |
| Left ventricle (mg) | 115.2 ± 3.5 (n = 32) | 115.5 ± 3.0 (n = 31) | 85.2 ± 2.2## (n = 18) | 77.3 ± 1.9$ (n = 18) |
| Right ventricle (mg) | 30.7 ± 1.3 (n = 31) | 27.0 ± 1.0# (n = 31) | 19.5 ± 1.1## (n = 18) | 18.2 ± 0.8$ (n = 18) |
| Atria (mg) | 11.0 ± 0.8 (n = 28) | 11.2 ± 0.5 (n = 31) | 6.3 ± 0.5## (n = 18) | 6.8 ± 0.5$ (n = 16) |
| Tibia length (mm) | 17.3 ± 0.1 (n = 32) | 17.3 ± 0.1 (n = 31) | 16.7 ± 0.1 (n = 18) | 16.9 ± 0.1 (n = 18) |
#P < 0.05, ##P < 0.0001 vs non-diabetic + vehicle; $P < 0.0001 vs non-diabetic + lipoxin A4 (2-way ANOVA, Fisher’s post hoc for multiple comparisons)